Clinical Trials Logo

Filter by:
NCT ID: NCT00389155 Completed - Bladder Cancer Clinical Trials

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Start date: January 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to test an investigational drug, vinflunine (BMS-710485), in combination with gemcitabine in patients with Transitional Cell Carcinoma who cannot be treated with cisplatin. This study will help to determine whether vinflunine in combination with gemcitabine will extend the time period until further growth of the tumor more than gemcitabine alone.

NCT ID: NCT00388726 Completed - Breast Cancer Clinical Trials

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.

NCT ID: NCT00388505 Completed - Cystic Fibrosis Clinical Trials

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

EAGER
Start date: February 2006
Phase: Phase 3
Study type: Interventional

This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler

NCT ID: NCT00387764 Completed - Clinical trials for Carcinoma, Renal Cell

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Start date: September 2006
Phase: Phase 3
Study type: Interventional

This is an open-label, international, multi-center study designed to provide access to pazopanib for subjects who have been enrolled in the Phase III renal cell carcinoma study (VEG105192) and have progressed on placebo. Subjects will receive 800 mg pazopanib once daily. The study treatment will continue until subjects experience disease progression, unacceptable toxicity, withdrawal of consent, or death. The primary objective of the study is to evaluate the safety and tolerability of pazopanib for the treatment of renal cell carcinoma. The secondary objectives of the study are to assess response rate (defined as complete response or partial response), progression-free survival, and overall survival. Response rates will be collected per investigator assessment (no central review). Subjects will have a CT/MRI scan every 6 weeks until week 24 and every 12 weeks thereafter.

NCT ID: NCT00387725 Completed - Healthy Clinical Trials

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

Start date: November 2006
Phase: Phase 2
Study type: Interventional

Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents

NCT ID: NCT00387569 Completed - Healthy Clinical Trials

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

Start date: October 2006
Phase: Phase 1
Study type: Interventional

A study to assess the safety of an investigational meningitis vaccine in toddlers and their immune response to it.

NCT ID: NCT00387309 Completed - Clinical trials for Post Operative Bowel Dysfunction

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Start date: December 2006
Phase: Phase 3
Study type: Interventional

Primary Objective: In subjects who have undergone segmental colectomy, the time between the end of surgery and first bowel movement is significantly shorter with the investigational MOA-728 regimen than with a placebo regimen.

NCT ID: NCT00387257 Completed - Atherosclerosis Clinical Trials

Effect Of Rilapladib (SB-659032) On Platelet Aggregation

Start date: October 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

NCT ID: NCT00387088 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium / Respimat One Year Study in COPD.

Start date: September 2006
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.

NCT ID: NCT00386360 Completed - Osteopenia Clinical Trials

Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method

Start date: April 2006
Phase: Phase 3
Study type: Interventional

The primary purpose of the protocol is to evaluate the sensitivity of 3D-pQCT (3D-Peripheral Quantitative Computed Tomography) technology to detect minute changes in bone microarchitecture.